Balance Sheet
Accounts PayablesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityOther Accumulated ExpensesPayablesPrepaid AssetsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Marker Therapeutics (MRKR) Common Equity (2016 - 2025)

Historic Common Equity for Marker Therapeutics (MRKR) over the last 11 years, with Q3 2025 value amounting to $18.4 million.

  • Marker Therapeutics' Common Equity rose 14684.49% to $18.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $18.4 million, marking a year-over-year increase of 14684.49%. This contributed to the annual value of $18.6 million for FY2024, which is 3206.44% up from last year.
  • Marker Therapeutics' Common Equity amounted to $18.4 million in Q3 2025, which was up 14684.49% from $10.5 million recorded in Q2 2025.
  • In the past 5 years, Marker Therapeutics' Common Equity ranged from a high of $72.5 million in Q1 2021 and a low of $7.4 million during Q3 2024
  • For the 5-year period, Marker Therapeutics' Common Equity averaged around $26.0 million, with its median value being $18.6 million (2024).
  • Its Common Equity has fluctuated over the past 5 years, first plummeted by 5676.96% in 2022, then soared by 14684.49% in 2025.
  • Quarter analysis of 5 years shows Marker Therapeutics' Common Equity stood at $44.0 million in 2021, then crashed by 55.44% to $19.6 million in 2022, then dropped by 28.31% to $14.1 million in 2023, then soared by 32.06% to $18.6 million in 2024, then decreased by 0.91% to $18.4 million in 2025.
  • Its Common Equity was $18.4 million in Q3 2025, compared to $10.5 million in Q2 2025 and $14.5 million in Q1 2025.